Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID05812755

The Effects of Soluble Guanylyl Cyclase Stimulation on Perioperative Vascular Reactivity and Organ Injury in Cardiac Surgery

Led by Vanderbilt University Medical Center · Updated on 2025-07-08

170

Participants Needed

1

Research Sites

47 weeks

Total Duration

On this page

Sponsors

V

Vanderbilt University Medical Center

Lead Sponsor

N

National Heart, Lung, and Blood Institute (NHLBI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the effects of medications called soluble guanylyl cyclase stimulators on blood vessel function and markers of kidney and brain injury in patients undergoing heart surgery. The study aims to find out if stimulating soluble guanylyl cyclase with a drug called vericiguat improves blood vessel function and reduces injury markers compared to a placebo. This research will help understand why some patients experience kidney and brain problems after heart surgery. Participants will be randomly assigned to receive either vericiguat, an oral medication given once daily at 10 mg for three days starting two days before surgery through the day of surgery, or a matching placebo under the same schedule. Vascular function will be measured using ultrasound and direct tests of artery relaxation outside the body. Blood and urine samples will be collected to measure markers of brain and kidney injury. During the study, participants will have assessments on the day of surgery and through two days after surgery. These include tests of blood vessel function, measurements of specific proteins related to brain and kidney damage, and markers of inflammation and blood clotting. Researchers will monitor how well the blood vessels respond and measure injury markers over time to understand the effects of vericiguat. Participation will last through the immediate perioperative period with careful monitoring of outcomes and safety.

CONDITIONS

Brief Title

SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Scheduled for elective open-heart surgery involving sternotomy or thoracotomy
Not Eligible

You will not qualify if you...

  • Intolerance to vericiguat
  • Current use of other soluble guanylyl cyclase stimulators or phosphodiesterase-5 inhibitors
  • Pregnancy or breastfeeding
  • Renal replacement therapy within 30 days prior to screening
  • Estimated glomerular filtration rate less than 15 ml/min per 1.73 m2 at screening
  • Systolic blood pressure less than 120 mmHg at screening
  • Prior kidney transplantation
  • History of significant liver dysfunction (Child-Pugh class C)
  • Surgery planned with circulatory arrest
  • Surgery for major congenital heart defect
  • Use of extracorporeal membrane oxygenation before surgery
  • Active systemic infection or surgery for infectious endocarditis
  • Ventricular assist device or intraaortic balloon pump support before surgery
  • Prisoners

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Run-in Period

Duration - 2 days

Participants take the assigned oral medication (vericiguat or placebo) once daily starting 2 days prior to their elective cardiac surgery.

1 to 2 visits before surgery

Treatment

Duration - Day of surgery

Participants continue the assigned oral medication on the day of surgery while vascular function assessments and blood and urine samples are collected to measure markers of organ injury.

1 surgery day visit (in-person)

Post-operative Follow-up

Duration - 3 days

Participants are monitored for organ injury markers and vascular function through postoperative day 2.

Up to 3 visits (in-person) through postoperative day 2

Trial Site Locations

Total: 1 location

1

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37204

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Similar Trials

FLOWGRAFT Post-Market Clinical Follow-up Study in Patients T...

Vascular Diseases

Actively Recruiting

1 location

A Prospective, Multicenter, Open-label, Randomized Controlle...

Brain Disease

Actively Recruiting

1 location

A Prospective, Multicenter, Randomized Controlled Trial to I...

Cardiovascular Diseases

Actively Recruiting

13 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here